T2 Biosystems, Prxcision announce co-marketing collaboration

T2 Biosystems and Prxcision have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections and sepsis, and combat the escalating crisis of antibiotic resistance. “Our platform delivers real-time insights that were once unimaginable,” said Paul Ambrose, CEO of Prxcision, Inc. “pRxcision brings cutting-edge AI to the patient’s bedside-empowering clinicians to navigate complex decisions with confidence. We are thrilled about this collaboration and believe it can accelerate the adoption of our technology, driving significant improvements in hospitals across the country.”